Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | HTR6 | P50406 | 5/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2389471 | 1.00 | MAPT (0.57) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1845533 | 0.83 | MAPT (0.74) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2390382 | 0.83 | MAPT (0.58) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12684748 | 0.78 | MAPT (0.69) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1842067 | 0.78 | MAPT (0.72) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1844417 | 0.78 | MAPT (0.65) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2391047 | 0.77 | MAPT (0.70) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1843870 | 0.76 | MAPT (0.67) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12684805 | 0.76 | MAPT (0.74) | MAPTNPSR1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16297415 | 0.75 | MAPT (0.52) | MAPTALDH1A1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2320897-A1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | Treventis Corporation (US) | 2011-05-18 | — | — | EP | claimed |
| WO-2010025375-A1 | COMPOSITIONS AND METHODS OF TREATING AMYLOID DISEASE | TREVENTIS CORPORATION (US) | 2010-03-04 | — | — | WO | claimed |
| US-8420640-B2 | Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine | TREVENTIS CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | TREVENTIS CORPORATION | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | PSEN1, PSEN2, APP | MAPT 10/4885NPSR1 717/4885CYP1A2 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.